INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2018

Elevated cholesterol is linked to breast cancer risk and poor prognosis, while cholesterol-lowering medication appears protective against recurrence.

This review examines clinical and preclinical data on the role of cholesterol and its metabolite, 27-hydroxycholesterol (27-OHC), in breast cancer pathophysiology. Cholesterol has emerged as a risk factor for breast cancer onset, and elevated cholesterol is associated with poor prognosis. While cholesterol-lowering medication is not associated with breast cancer risk, it appears protective against recurrence.

Shows an association, not proof of cause and effect.

Study type
Narrative review
Who was studied
Patients with breast cancer or at risk for breast cancer
What was measured
Breast cancer onset, prognosis, and recurrence

THE PAPER

The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.

Nelson ER. Mol Cell Endocrinol, 2018.

PubMed 28919300 ↗DOI 10.1016/j.mce.2017.09.021 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.